ClinicalTrials.gg
CompletedNCT01545245Updated Dec 8, 2014

Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants

An observational study in Atopic Asthma and Recurrent Wheezing, sponsored by Tokai University. Completed. Open to participants aged 3 Years to 3 Years. Per ClinicalTrials.gov, last updated 2014-12-08.

Sponsored by Tokai University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
343
Ages
3 Years to 3 Years
Sex
All
01

Study summary

The primary objective of the study is to determine whether the incidence of atopic asthma after three years old may be suppressed in the children who were born as preterm infants and prophylactically treated with palivizumab for respiratory syncytial (RS) virus infections during the infancy.

The secondary objective is to determine whether the incidence of recurrent wheezing after three years old may be suppressed in the children who were born as preterm infants and prophylactically treated with palivizumab for RS virus infections during the infancy.

02

Conditions studied

  • Atopic Asthma
  • Recurrent Wheezing

Browse trials for

Keywords

  • atopic asthma
  • recurrent wheezing
  • preterm infants
  • palivizumab
  • respiratory syncytial virus
  • RSV
03

In context

Respiratory Sounds

189 studies on the registry are indexed under Respiratory Sounds; 41 are open to participants now.

This study's enrollment of 343 is above the median of 109 across 82 observational studies indexed under Respiratory Sounds.

Browse Respiratory Sounds studies →

Lead sponsor

Tokai University is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The children who are participating in another on-going study, "Effect of Palivizumab on Later Recurrent Wheezing in Preterm Infants (ClinicalTrials.gov Identifier: NCT01072552)" and whose parents or legal guardian provide informed consent in writing for continuing participation in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants born July \~ December 2007 at 33\~35 weeks of gestation
  • Infants administered at least 3 doses of palivizumab during the first 6 months of life (Palivizumab treated)
  • Infants not administered any doses of palivizumab during the first 6 months of life (Palivizumab untreated)

Exclusion criteria

Exclusion Criteria:

  • Intrauterine growth retardation (less than -2.5SD)
  • Infants with chronic lung disease (CLD) or other respiratory disease
  • Infants received mechanical ventilation
  • Infants with chronic heart disease (CHD) or congenital anomaly (such as immunodeficiency)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
343 participants (actual)
Biospecimen retention
Samples without dna

Groups and cohorts

  • Treated

    Palivizumab treated

  • Untreated

    Palivizumab untreated

06

What researchers measure

Primary outcomes

  1. The incidence of atopic asthma after three years old in the children who were born as preterm infants and prophylactically treated with palivizumab for RS virus infections during the infancy

    Time frame: For three years

Secondary outcomes

  1. The incidence of recurrent wheezing after three years old in the children who were born as preterm infants and prophylactically treated with palivizumab for RS virus infections during the infancy

    Time frame: For three years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Mochizuki H, Kusuda S, Okada K, Yoshihara S, Furuya H, Simoes EAF; Scientific Committee for Elucidation of Infantile Asthma. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study. Am J Respir Crit Care Med. 2017 Jul 1;196(1):29-38. doi: 10.1164/rccm.201609-1812OC. Erratum In: Am J Respir Crit Care Med. 2018 Mar 1;197(5):685. doi: 10.1164/rccm.1975Erratum. PubMed 28152315 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2012
First posted
Mar 6, 2012
Start
Jul 2010
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Last update
Dec 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01545245
Lead sponsor
Tokai University
Collaborators
Scientific Committee for Elucidation of Infantile Asthma
Responsible party
Hiroyuki Mochizuki (Professor, Department of Pediatrics, Tokai University) — Principal investigator
First posted
Mar 6, 2012
Start date
Jul 2010
Primary completion
Jan 2014
Completion
Jan 2014
Last update
Dec 8, 2014

Study contacts

Hiroyuki Mochizuki, M.D., Ph.D.,
principal investigator · Professor, Department of Pediatrics, Tokai University School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion